Levi & Korsinsky is investigating the Board of Directors of Clarient, Inc. (“Clarient” or the “Company”) (NasdaqCM: CLRT) for possible breaches of fiduciary duty and other violations of state law in connection with their attempt to sell the Company to GE Healthcare, a unit of General Electric Company (NYSE: GE). Under the terms of the transaction, Clarient shareholders will receive $5.00 in cash for each Clarient common share and $20.00 in cash for each preferred share. The transaction values Clarient at approximately $580 million, net of cash and investments as of June 30, 2010. The Board of Directors of Clarient has approved the transaction and unanimously recommended that Clarient stockholders tender their shares in the transaction.
Click here to learn how to join the action:
, or call: 877-363-5972.
The investigation concerns whether the Clarient Board of Directors breached their fiduciary duties to Clarient stockholders by failing to adequately shop the Company before entering into this transaction and whether GE Healthcare is underpaying for Clarient shares, thus unlawfully harming Clarient stockholders. In particular, at least one analyst set a price target for Clarient common stock at $6.00 per share.
If you own common stock in Clarient and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at
or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit
Levi & Korsinsky has expertise in prosecuting investor securities litigation and extensive experience in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major litigations involving mergers and acquisitions. For more information, please feel free to contact any of the attorneys listed below.